Surgical Versus Percutaneous Revascularization in Patients With Reduced Left Ventricular Function (STICH 3.0-NL)
Recruiting now · Not applicable
Conditions studied: Coronary Artery Disease, Coronary Artery Disease (CAD), Multivessel Coronary Artery Disease, CABG, CABG in Low EF, Heart Failure, PCI, Revascularization
In brief
This randomized multicenter trial compares coronary artery bypass grafting (CABG) with percutaneous coronary intervention (PCI) in 358 patients with ischemic left ventricular dysfunction and multivessel coronary disease. The study evaluates differences in survival, major cardiovascular events, and quality of life over 4 years, and contributes to the international STICH 3.0 collaboration assessing long-term outcomes.
Key facts
- Study ID
- NCT07269366
- Run by
- University Medical Center Groningen
- People needed
- 358
- Starts
- 2026-05-01
- Expected to finish
- 2034-05-01
- Last updated by the study team
- 2026-05-12
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥ 18 years
- LVEF≤ 40%
- Angina pectoris, CCS≥2 and/or hospitalization for ACS or heart failure within 1 year prior to randomization
- Multivessel CAD (2-3 vessel-disease with coronary lesions >70% and involvement of proximal LAD, and/or LM stenosis of >50%). Target vessels are determined by the local Heart Time
- Clinical and angiographical characteristics suitable for isolated coronary revascularization both by CABG or PCI according to the judgment of the local Heart Team
- Written informed consent
You may not qualify if…
- ACS < 48 hours before randomization
- Valvular/structural heart disease requiring intervention
- Contra-indications to DAPT
- Non-cardiac condition with life expectancy < 1 year
- Previous CABG
- Decompensated HF at the time of inclusion
Where it is running
- University Medical Center Groningen — Groningen, Netherlands (enrolling)
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.